Does Rallies show Form 4 insider transactions for CLDI?

Yes. Rallies tracks CLDI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CLDI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CLDI. It does not provide personalized investment advice.

CLDI (Calidi Biotherapeutics, Inc.) Stock Analysis - Insider Trades

Calidi Biotherapeutics, Inc. (CLDI) is a publicly traded Healthcare sector company. As of May 21, 2026, CLDI trades at $0.18 with a market cap of $2.79M and a P/E ratio of -0.03. CLDI moved -8.04% today. Year to date, CLDI is -85.53%; over the trailing twelve months it is -96.84%. Its 52-week range spans $0.16 to $46.68. Rallies surfaces CLDI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CLDI stock inside the company?

Recent CLDI insider activity includes Camaisa Allan sold 850, Schoeneck James A bought 75.00K, Poma Eric E bought 25.00K, Leftwich Scott bought 125.00K, and Jackson Andrew C. bought 2.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CLDI Key Metrics

Key financial metrics for CLDI
Metric	Value
Price	$0.18
Market Cap	$2.79M
P/E Ratio	-0.03
EPS	$-5.95
Dividend Yield	0.00%
52-Week High	$46.68
52-Week Low	$0.16
Volume	186.46K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-20.06M
Gross Margin	0.00%

Recent CLDI Insider Trades

Camaisa Allan sold 850 (~$1.24K) on Dec 12, 2025.
Schoeneck James A bought 75.00K (~$150.00K) on Aug 21, 2025.
Poma Eric E bought 25.00K (~$50.00K) on Aug 21, 2025.
Leftwich Scott bought 125.00K (~$250.00K) on Aug 21, 2025.
Jackson Andrew C. bought 2.50K (~$5.00K) on Aug 21, 2025.

Latest CLDI News

Calidi Biotherapeutics Narrows Q1 Net Loss to $4.4M, Raises Cash to $6.6M and Secures AI Partnership — May 14, 2026
Calidi to Unveil CLD-401 IL-15 Virotherapy Data, Aims for IND Filing by Year-End — May 13, 2026
Calidi Biotherapeutics Taps TransferAI’s Sofie AI to Accelerate CLD-401 IND Filing by Year-End — Apr 29, 2026
Calidi Reveals CLD-401 Tumor-Targeted IL-15 Superagonist Data, Plans IND by Year-End — Apr 21, 2026
Calidi to Present RedTail Preclinical EEV Data, Plans IND Filing for CLD-401 — Apr 14, 2026

CLDI Analyst Consensus

CLDI analyst coverage data. Average price target: $0.00.

Common questions about CLDI

Who is trading CLDI stock inside the company?: Recent CLDI insider activity includes Camaisa Allan sold 850, Schoeneck James A bought 75.00K, Poma Eric E bought 25.00K, Leftwich Scott bought 125.00K, and Jackson Andrew C. bought 2.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CLDI?: Yes. Rallies tracks CLDI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CLDI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CLDI. It does not provide personalized investment advice.